CYTOMX THERAPEUTICS INC. WKN: A14158 ISIN: US23284F1057 Kürzel: CTMX Forum: Aktien Thema: Hauptdiskussion

Ke preis ja auch fast auf aktuellen kurs 👍

Alles nicht wild. Nach KE 390 Mio Cash

Common stock CytomX Therapeutics, Inc. (“CytomX” or the “Company”) is offering $75,000,000 of shares of our common stock, par value $0.00001 per share, pursuant to this prospectus supplement and the accompanying prospectus relating to the shares to be sold by it. Our common stock is listed on The Nasdaq Global Select Market under the symbol “CTMX.” On January 15, 2021, the last reported sale price of our common stock on The Nasdaq Global Select Market was $7.93 per share. Based on an assumed offering price of $7.93 per share, we would expect to offer 9,457,755 shares of our common stock in this offering.

Wie siehst das?

Soviel zum Thema entspanntes anlegen :-)

KE 75 Mio

https://ih.advfn.com/p.php?pid=nmona&article=84124991

Ziel Gap Close😁

Neue Options an MA.

Entspanntes Anlegen.

Unser schlafender Riese präsentiert sich: Stern IR Virtual Conference am 11. Januar 2021

Heute letzter Kauf. Kann losgehen ✌

FUTURE MILESTONES • CX-2009 Phase 2 HR+/HER2- Breast Cancer • CX-2009 + CX-072 Phase 2 TNBC • CX-2029 Phase 2 expansions • BMS-986249 randomized Phase 2 • CX-904 (EGFR-CD3) IND • Additional IND(s) from internal and partnered discovery programs

Keine Schulden, keine Warrants👍👍👍

Da ist laut Präsentation einiges los. Hammerkurs, zur Zeit.

Growing evidence Probody Platform can unlock clinical potential in previously undruggable targets and enable improved immune checkpoint inhibition Phase 1 data for CX-2029 (Anti-CD71) underpin recent $40 million AbbVie milestone and support Phase 2 expansion studies - CX-2029 global co-development alliance with AbbVie with 35% US commercial rights retained Phase 2 data for CX-2009 (Anti-CD166) support Breast Cancer Phase 2 Strategy CX-2009 remains wholly-owned by CytomX Continued progress with Probody Checkpoint Inhibitor programs • BMS-986249 (Anti-CTLA4) Phase 1 data support ongoing randomized Phase 2 expansion in melanoma • CX-072 (Anti-PD-L1) durable clinical benefit in multiple tumor types with favorable tolerability profile